I want to be contrarian about this and I can't quite manage it, which annoys me, so let's just state the numbers.

The RTS,S malaria vaccine (branded Mosquirix) is not new — WHO recommended it in 2021 — but the four-year real-world evaluation published this year is the first dataset large enough to answer the question everyone hedges on: does a partially effective vaccine (RTS,S's efficacy in trials topped out around 30-40% against clinical malaria) actually move mortality when deployed at population scale through ordinary health systems, not a controlled trial?

Per WHO's May 2026 update and the rigorous evaluation published in The Lancet, the answer across Ghana, Kenya and Malawi is yes: roughly 1 in 8 deaths among children eligible to receive the vaccine were averted over the four-year follow-up.

WHO's own estimate lands at about one life saved for every 200 children vaccinated — modest per-dose, enormous at 39 million doses delivered.

The distribution curve is the part worth sitting with. As of January 2026, Gavi has supported the introduction of malaria vaccines into routine immunization schedules in 25 African countries, and nine of the ten highest-burden countries are now rolling out widely. 3 million, a 169% jump over the prior year — this is not a pilot anymore, it's the immunization schedule.

3 million, a 32% drop, with a steeper 38% decline specifically among children under five, the group with the highest case-fatality risk.

None of this replaces bed nets, indoor spraying, or the newer dual-active-ingredient nets — WHO and Gavi are explicit that the vaccine is additive, not a substitute.

And RTS,S efficacy genuinely does wane over time, which is why the WHO evaluation matters more than a trial readout: it's measuring what four years of imperfect, real-world, multi-dose delivery through public clinics actually buys you, not what a controlled cohort achieves under ideal conditions.

That distinction is exactly the one that gets lost when a story about an intervention that "worked in the trial" becomes a claim about what it will do once a government owns delivery — a gap I've written about elsewhere and don't get to dodge just because this time the outcome I'd bet against turned out fine.

Funding is the honest asterisk.

Nature's Africa coverage of the rollout in 2025 flagged it as historic and simultaneously underfunded — scale-up commitments from Gavi and country budgets have not fully caught up to eligible-population size, and WHO's African regional office is on record warning that funding pressure threatens to slow further expansion just as the vaccine's population-level benefit becomes measurable.

So: real, replicated across three countries, independently evaluated, and still short of the money it would take to reach everyone eligible.